Lynozyfic⢠(linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment · December 10, 2025 · 6 pages
Preview the first 2 pages of this press release
Create a free account to start reading
Full documents are included with Professional
Earnings release
17 pages
Oct 28, 2025
Quarterly report
92 pages
Oct 28, 2025
Presentation
Oct 2025 - REGN Corporate Presentation
38 pages
Presentation
REGN Roundtable - Factor XI
36 pages
Presentation
Lynozyfic - Regeneron Roundtable FINAL
31 pages
Press release
Lynozyfic⢠(linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment
6 pages
Dec 10, 2025
Press release
Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet
4 pages
Nov 10, 2025